Psychedelic Stocks MindMed (OTCMKTS:MMEDF) Completes Pre-Investigational New Drug Meeting With The FDA For LSD Development For Anxiety Treatment By Larry Zweig January 05, 2021 MindMed (OTCMKTS:MMEDF) has announced the completion of a pre-Investigational New Drug (IND) meeting with the FDA for lysergic acid diethylamide (LSD) development as anxiety disorder therapy. MindMed on a pathway to develop anxiet...
Psychedelic Stocks Mind Medicine (MindMed) Inc. (OTCMKTS:MMEDF) Successfully Completes Pre-IND Meeting For LSD Therapy In Anxiety Disorder By Larry Zweig December 15, 2020 Mind Medicine (MindMed) Inc. (OTCMKTS:MMEDF) has successfully completed a pre-Investigational New Drug (IND) meeting with the FDA regarding lysergic acid diethylamide (LSD) aided therapy development for anxiety disorder. MindMed d...
Psychedelic Stocks Psychedelics Can Stimulate Neurogenesis In Patients Neurodegenerative Disorders, New Study Says By Larry Zweig December 02, 2020 There has been growing research on psychedelic drugs such as LSD, mescaline, and psilocybin on their potential to treat psychiatric conditions like depression and major depressive disorder. A new study has revealed that N, N-dimet...
